Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Nxera’s 50 Billion Yen Global Sales Goal “Conservative Figure”: Japan Chief
Nxera Pharma has set out a global sales target of 50 billion yen by 2030, but the company’s new Japan president calls it “a conservative figure,” noting that the challenge will be how to surpass this line. Makoto Sugita, who…
To read the full story
Related Article
- Nxera Pharma Eyes 50 Billion Yen in Global Revenue by 2030: CEO
November 7, 2024
- Ex-BMS Exec Sugita Tapped as President of Nxera Pharma Japan
October 2, 2024
BUSINESS
- Takeda’s Narcolepsy Med Orzeyful Now Available in Japan, China
October 15, 2026
- JCR’s Izcargo Reels in Conditional Approval in Kuwait
October 15, 2026
- Nxera Licenses Quviviq to Taiwan’s Synmosa in 8 APAC Markets
October 15, 2026
- Rhythm’s Imcivree Debuts in Japan for Acquired Hypothalamic Obesity
October 15, 2026
- Pfizer to Drop Avastin, Herceptin Biosimilars in Japan, Halving Portfolio
October 14, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…